Sara Hurvitz,
Kelly McCann
Elsevier Health Sciences
e druk, 2018
9780323581226
HER2-Positive Breast Cancer
Specificaties
Paperback, blz.
|
Engels
Elsevier Health Sciences |
e druk, 2018
ISBN13: 9780323581226
Rubricering
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive.
Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. Includes a timely section on innovative future therapies.
Specificaties
Inhoudsopgave
Background/testing <p>1. The HER2 alteration in breast cancer</p> <p>2. HER2 testing in the era of changing guidelines</p> <p>Advanced Disease</p> <p>3. Optimal first-line treatment of HER2+ advanced disease</p> <p>4. Second line therapy and beyond</p> <p>5. HER2+ CNS metastases</p> <p>Therapeutics</p> <p>6. Neoadjuvant therapy</p> <p>7. Adjuvant therapy</p> <p>8. Outcomes based on HR status in early stage disease</p> <p>9. De-escalation of therapy for small tumor</p> <p>Toxicity considerations</p> <p>10. Cardiac toxicity of HER2-targeted regimens</p> <p>11. Non-cardiac toxicity of HER2-targeted therapy</p> <p>Therapies on the horizon</p> <p>12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)</p> <p>13. Harnessing the immune system in HER2+ disease</p> <p>14. Biosimilars</p>